, along with other data from the Arabidopsis 1001 Genomes Project, can be used to relate phenotypic variation to the underlying genotypic variation observed in GWAS.
Comparative genome studies have already provided many useful results. A pioneering study 8 that examined 107 phenotypes of Arabidopsis in 96 diverse, genotyped lines found associations between several adaptive phenotypes and sequence variations. Similar approaches have been used in a study of 517 local varieties of rice to identify genetic variation associated with 14 useful agronomic traits 11 . Another genome-wide study has shown that adaptation of certain strains of Arabidopsis to high salt conditions is associated with sequence variation in a gene that encodes a sodium-transporter protein 12 . GWAS in general are also showing exceptional promise for identifying causal sequence variation in complex emergent traits in plants, such as crop yield and quality 13 . The application of high-throughput DNA sequencing and genome-capture technology will inevitably lead to the large-scale resequencing of the genomes of crop species, in much the same way that the tiny, relatively simple Arabidopsis genome has been re-sequenced in the three new studies [2] [3] [4] . These technologies will revolutionize plant breeding by enabling a wide variety of phenotypic variations to be mined for their associated sequence variations, which can then be used to select breeding lines 13 . This will substantially reduce the time taken to create varieties of crop plants that are adapted to cope with changes in growing conditions or new pathogens, and/or to improve crop yield. ■ 
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VACCINOLOGY
Precisely tuned antibodies nab HIV
Newly discovered neutralizing antibodies that target sites on the envelope proteins of HIV-1 provide a window on how some of the most powerful of these antibodies acquire their potency and breadth of activity. See Letter p.466
T he huge variation among HIV-1 viruses presents a formidable challenge for the development of an effective vaccine: a successful vaccine would probably need to elicit the production of broadly acting neutralizing antibodies. The challenge is even more daunting when one considers that HIV-1 has evolved many ways to evade the neutralizing antibodies of infected subjects 1 . Nevertheless, a few HIV-infected individuals (dubbed 'elite neutralizers') do develop antibodies that potently nullify diverse HIV-1 strains. The discovery and characterization of these powerful antibodies is gaining momentum -as evidenced by three exciting new studies [2] [3] [4] , including one by Walker et al. 2 on page 466 of this issue. Until 2009, it was difficult to isolate broadly neutralizing antibodies against HIV-1, and only a few had been described (Table 1) . Such antibodies are generally derived as monoclonal antibodies, obtained from individual B cellsthe immune cells that function as factories for antibody production. Two such anti bodies (2F5 and 4E10) target the transmembrane glyco protein gp41 of HIV-1, which anchors the viral envelope to the underlying virus particle 5, 6 ( Fig. 1) . Two other antibodies (b12 and 2G12) target the outer envelope protein gp120. Of these, b12 blocks the binding site to CD4 (ref. 7) , the main receptor for HIV on the surface of immune cells called T cells, whereas 2G12 binds to glycans 6 , sugar components on the HIV-1 envelope. Over the past two years, a succession of studies has identified further monoclonal antibodies that target gp120. Antibodies that bind to newly discovered sites overlapping the CD4 binding site -HJ16 and particularly VRC01 -show greatly improved breadth of action and potency over those already known 8, 9 , and the antibodies PG9, PG16 and CH01 to CH04 target a previously unknown quarternary structure on gp120 that includes binding sites in its V2 and V3 loops 10, 11 . Walker et al. 2 describe a diverse set of monoclonal antibodies that bind to a newly identified site at the base of the V3 variable loop. For antibodies from at least one of the HIV-infected subjects, this site includes glycans, which, ironically, usually assemble on the envelope to prevent antibody binding. These new antibodies are tenfold more potent than previously described broadly acting monoclonal antibodies, but maintain activity against diverse HIV-1 viruses even at relatively low doses.
In the two other reports, Scheid et al. 3 and Wu et al. 4 investigate large numbers of newly identified monoclonal antibodies that they amplified from samples obtained from several elite neutralizers; many of these antibodies have similar specificity and breadth of activity to VRC01 -until now the most potent and broadly acting antibody. Scheid and colleagues use a new approach that increases the recovery of antibody genes from B cells and, notably, they confirm that such antibodies were circulating in the serum of an elite neutralizer. Both reports are a reassuring indication that VRC01-like antibodies are not extremely rare but are repeatedly generated, at least by elite neutralizers.
The antibodies present in adult human blood recognize hundreds of millions of different foreign proteins. Yet the human genome has only a limited number of genes that encode antibodies. Antibody diversity is partly achieved by a process called affinity maturation, which generates mutations in the antibody genes in B cells. If single B cells carrying mutated antibodies on their surface bind efficiently to a target protein antigen, this stimulates the cells to multiply and to produce larger amounts of the antibodies. To date, all of the broad and potent neutralizing antibodies that target the HIV envelope (particularly VRC01-like antibodies) have been shown to contain many mutations and seem to have gone through repeated rounds of mutagenesis and selection of antibody variants.
Wu et al. 4 combine in-depth sequencing and crystal-structure analyses to examine the diversity of VRC01-like antibody sequences in HIV-infected patients. Their data provide a fascinating insight into the families of VRC01-like antibody variants in individual subjects: there is an increasing divergence from the original antibody gene, the breadth and potency increasing with the number of mutations or amino-acid substitutions in the antibody sequence. Remarkably, the most broadly acting and potent antibodies from the infected individuals had converged on structures similar to VRC01 that optimized interactions with the site on the envelope that makes the first contact with CD4. The related experiments of Scheid et al. support these observations. Studies over the past few years, culminating in the reports summarized here [2] [3] [4] , have shown beyond doubt that HIV-1-positive subjects can elicit potent and broadly active neutralizing antibodies and that there are several exposed and relatively invariant sites on the viral envelope that are vulnerable to such antibodies.
These observations have obvious implications for the development of HIV vaccines. However, the optimism they bring needs to be tempered with caution, at least for now. This is because it is unclear how immunogenic molecules that will elicit such antibodies could be designed and administered. The current studies investigate the neutralizing antibodies themselves and the structure of envelope target molecules to which they bind, but do not address the design of immunogens or immunization strategies that could induce similar antibodies.
Nevertheless, the studies highlight two major problems. First, several target molecules of the broad, potent antibodies -including the glycans identified by Walker et al. 2 -are notoriously inefficient as immunogens, and it is not clear how the dramatic improvements required to make them effective could be achieved. Second, as discussed, the most potent and broadly acting antibodies have undergone substantial affinity maturation over a long period. It is not known whether the same features can be achieved with limited vaccinations in a much shorter process. Wu and colleagues 4 argue that knowing the structures and sequences of antibodies that are intermediates or precursors to the most effective versions will help in designing and identifying envelope immunogens that can steer developing antibodies towards breadth and potency.
Key questions remain. Why do so few HIVinfected individuals develop broad and potent neutralizing antibodies? And are there further, as yet unknown, envelope targets for neutralizing antibodies? One final piece of information in Walker and co-workers' report is derived from a concept in traditional vaccinology. Using theoretical modelling, they argue that a combination of antibodies possessing different target specificities will increase the breadth and potency of neutralization, as described in a previous study 12 . Taking into account the increasing number of potential targets for broadly neutralizing antibodies on the HIV-1 envelope, it is possible that a vaccine able to elicit a combination of antibodies targeting different sites will confer breadth, potency and protection, even if individual antibody components don't reach maximal neutralizing concentrations. ■ Neutralizing anti-HIV-1 antibodies
Paul R. Clapham is in the Program in
